Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Clinical diagnosis of ocular hypertension, exfoliative open-angle glaucoma, or pigment dispersion glaucoma in at least one eye (study eye).~* Be on a stable intraocular pressure (IOP) lowering regimen within 30 days of the Screening Visit.~* IOP considered safe in both eyes in such a way that should assure clinical stability of vision and optic nerve throughout the study period.~* Best corrected visual acuity of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in each eye.~* IOP between 19 and 35 mmHg in at least one eye (which would be the study eye) while on brimonidine/timolol fixed combination therapy.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of other primary or secondary glaucoma not listed in inclusion criteria #2.~* History of ocular herpes simplex.~* Abnormality preventing reliable applanation tonometry.~* Corneal dystrophies.~* Concurrent infectious/noninfectious conjunctivitis, keratitis, or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed.~* Intraocular conventional surgery or laser surgery in study eye(s) less than three months prior to the Screening Visit.~* Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.~* Progressive retinal or optic nerve disease from any cause.~* Use of systemic medications known to affect IOP which have not been on a stable course for 7 days prior to the Screening Visit or an anticipated change in the dosage during the course of the study.~* Pregnant or lactating.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZARGA (Type: EXPERIMENTAL): Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).